MedTrace Logo

Efficacy and Safety Study of SUNPG1623

NCT02980692 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 391

Last updated 2023-01-27

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623

Conditions

Interventions

DRUG

SUNPG1623 I

injection

DRUG

SUNPG1623 II

injection

DRUG

SUNPG1623 III

injection

DRUG

SUNPG1623 IV

injection

DRUG

PLACEBO

injection

Sponsors & Collaborators

  • Sun Pharmaceutical Industries Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-19
Primary Completion
2019-03-01
Completion
2019-09-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02980692 on ClinicalTrials.gov